Scientists at Universidade Miguel Hernández, in Alicante, Espanha, developed the MCH11 molecule, which inhibits alcohol cravings in experiments with mice. The compound acts on the brain’s endocannabinoid system, reducing ethanol consumption without compromising motor or cognitive skills. The research, published in the magazine Neuropharmacology, took place in 2025 and involved tests with male and female animals.
The results indicate that MCH11 blocks the enzyme monoacylglycerol lipase, known as MAGL, responsible for the degradation of 2-arachidonoylglycerol, or 2-AG. Essa action raises levels of 2-AG, a natural substance that regulates impulses and stress. The study aimed to treat alcohol use disorder, a condition that affects millions globally.
- Reduction in voluntary alcohol consumption by up to 50% in treated groups.
- Decrease in preference for ethanol in choice tests between water and alcoholic beverages.
- Anxiolytic effects observed, with less impulsivity in stressful situations.
The initiative arose from the need for more effective options for current therapies, which have limitations in adherence rates and effectiveness.
Mechanism of action in the brain
The MCH11 molecule directly interferes with the MAGL enzyme, present in brain regions linked to pleasure and reward. Essa inhibition preserves 2-AG, which modulates stress and withdrawal responses. Pesquisadores noticed changes in the expression of dopamine-related genes during testing.
In mice exposed to ethanol, the compound decreased motivation to drink in controlled settings. Molecular analysis confirmed impacts on the endocannabinoid system, without evidence of acute toxicity.
The process involved oral or injectable administration, with monitoring for four years in animal models.
Results observed in the experiments
Tests with mice demonstrated a drop in the volume of alcohol ingested after application of MCH11. Treated Animais consumed less ethanol in free sessions, with notable differences between sexes. Fêmeas showed faster impulse reduction responses.
The combination with topiramate, a medication approved for alcohol dependence, increased the effects in 30% of cases. Nenhum group exhibited impairments on memory or coordination tasks.
Mild antidepressant effects emerged as an additional benefit, regulating mood without external interventions.
Researchers recorded less activation in brain reward areas via functional imaging.
Variations by sex and initial implications
Differences between males and females have highlighted the need for personalized approaches to treatment. Machos responded with a greater reduction in initial consumption, while females benefited more in anxiety control. Esses patterns suggest hormonal influences on the endocannabinoid system.
The study included 200 mice, divided into control and treated groups, lasting 12 weeks per phase. Consistent Resultadoss reinforce the potential for human clinical trials.
The team plans tests in primates to validate safety in more complex organisms.
Preparation for clinical trials
The transition to humans requires large-scale dosing and bioavailability assessments. Initial Protocolos focuses on volunteers with mild to moderate alcohol use disorder. The molecule demonstrated stability in oral formulations, facilitating adhesion.
Partnerships with European institutions accelerate regulatory approvals. Preliminary Dados indicates a half-life of 24 hours in animal plasma, optimizing frequency of use.
Monitoring of side effects will occur in double-blind phases, prioritizing different age groups.
Phase I trials aim to recruit 50 participants in 2026, with an emphasis on craving and relapse metrics.
Advances in combination therapies
MCH11 integrates with existing treatments, such as naltrexone, to enhance the reduction of cravings. Estudos parallels test synergies with GABA inhibitors, common in detoxification protocols. Essa strategy targets success rates above 70% in annual follow-ups.
Additional research explores extended-release formulations to minimize plasma spikes. Colaborações with Spanish pharmaceutical companies finance expansions.
Results of coadministration with topiramate confirm the absence of adverse interactions in liver tissues.
The modular approach allows for adjustments based on patients’ genetic profiles.
Global context of alcoholic disorder
Alcohol use disorder represents a public health challenge, with 2.6 million deaths annually according to international data. Current pharmacological Terapias covers only 20% of severe cases due to side effects. MCH11 appears as a selective option, acting in underexplored pathways.
European statistics indicate a prevalence of 5% in adults, with a greater impact on young age groups. Programas prevention incorporates endocannabinoid inhibitors into draft guidelines.
Research initiatives funded by União Europeia prioritize compounds such as MCH11 to reduce hospital costs.
The focus on neurochemical mechanisms drives policies for access to innovative treatments.
